Compare State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF (FLRN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF vs GSK plc — how do they compare? State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.06B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 30× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and GSK plc pays a 3.9% dividend while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 16 Days and GSK plc for 93 Days on average.
| FLRN | GSK | |
|---|---|---|
Market Cap | $3.06B | $91.88B |
Volume | 6,296,473 | 7,730,529 |
Sector | Fixed Income | Health |
52-Week High | $30.86 | $61.18 |
52-Week Low | $30.65 | $43.24 |
Typical Hold Time | 16 Days | 93 Days |
Enterprise Value | — | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.77 with minimal daily movement (+0.07%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent quarterly dividends of $0.11, with recent institutional buying interest from Concurrent Investment Advisors. Current market focus centers on floating rate bonds' performance amid rising interest rate expectations.
FLRN offers exposure to investment-grade floating rate bonds with near-zero duration, positioning it as a potential hedge against rate hikes. Key risks include concentrated financial sector exposure and sensitivity to credit spread changes. The ETF's structure provides income stability but faces headwinds from potential economic slowdowns affecting corporate bond markets.
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF
FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
